Clinical Trial Results: Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial results for elenagen plasmid in combination with gemcitabine show efficacy in platinum-resistant ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Elenagen (plasmid) (elenagen plasmid)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: CureLab Oncology | Conditions: Ovarian Cancer, Platinum-resistant Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2026-08-24